Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/1b trial of PUR1900 for treatment of fungal infections in cystic fibrosis patients

Next Previous
Search
Trial Profile

A phase 1/1b trial of PUR1900 for treatment of fungal infections in cystic fibrosis patients

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itraconazole (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections
  • Focus Adverse reactions

Most Recent Events

  • 10 Mar 2017 According to a Pulmatrix media release, the company plans to initiate this study in 2017.
  • 10 Mar 2017 According to a Pulmatrix media release, the company plans to read out the data from trial in 2017.
  • 17 Jan 2017 According to a Pulmatrix media release, the U.S. Food & Drug Administration has designated PUR1900 as a Qualified Infectious Disease Product for the treatment of fungal infections in the lungs of cystic fibrosis patients.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top